Beta-blockers for control of hypertension: Controversy, evidence, and current practice

Shahid Akbar, John R Richards

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Hypertension remains one of the most pressing clinical problems in medicine around the globe. Treatment of hypertension has been evolving over the past few decades but remains a challenge for clinicians to achieve the targeted goals of blood pressure in their patients. Different classes of pharmacological agents are available to choose from, each with specific advantages and disadvantages. Beta-blockers have been a dependable group of drugs for many years for treatment of acute and chronic hypertension; however, their routine use for hypertension has lately been a subject of discussion and controversy. Beta-blockers have now been relegated to third-line treatment for hypertension in many countries. This chapter reviews the controversies surrounding the use of β-blockers for hypertension, newer classes of β-blockers, their comparative advantages over other antihypertensive drugs, clinical evidence, and limitations of their use.

Original languageEnglish (US)
Title of host publicationBeta-Blockers
Subtitle of host publicationPhysiological, Pharmacological and Therapeutic Implications
PublisherNova Science Publishers, Inc.
Pages45-78
Number of pages34
ISBN (Electronic)9781536133127
ISBN (Print)9781536133110
StatePublished - Jan 1 2018

Fingerprint

Hypertension
Antihypertensive Agents
Therapeutics
Medicine
Pharmacology
Blood Pressure
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Akbar, S., & Richards, J. R. (2018). Beta-blockers for control of hypertension: Controversy, evidence, and current practice. In Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications (pp. 45-78). Nova Science Publishers, Inc..

Beta-blockers for control of hypertension : Controversy, evidence, and current practice. / Akbar, Shahid; Richards, John R.

Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications. Nova Science Publishers, Inc., 2018. p. 45-78.

Research output: Chapter in Book/Report/Conference proceedingChapter

Akbar, S & Richards, JR 2018, Beta-blockers for control of hypertension: Controversy, evidence, and current practice. in Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications. Nova Science Publishers, Inc., pp. 45-78.
Akbar S, Richards JR. Beta-blockers for control of hypertension: Controversy, evidence, and current practice. In Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications. Nova Science Publishers, Inc. 2018. p. 45-78
Akbar, Shahid ; Richards, John R. / Beta-blockers for control of hypertension : Controversy, evidence, and current practice. Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications. Nova Science Publishers, Inc., 2018. pp. 45-78
@inbook{982063f15bd748c8b5610b5475503cf0,
title = "Beta-blockers for control of hypertension: Controversy, evidence, and current practice",
abstract = "Hypertension remains one of the most pressing clinical problems in medicine around the globe. Treatment of hypertension has been evolving over the past few decades but remains a challenge for clinicians to achieve the targeted goals of blood pressure in their patients. Different classes of pharmacological agents are available to choose from, each with specific advantages and disadvantages. Beta-blockers have been a dependable group of drugs for many years for treatment of acute and chronic hypertension; however, their routine use for hypertension has lately been a subject of discussion and controversy. Beta-blockers have now been relegated to third-line treatment for hypertension in many countries. This chapter reviews the controversies surrounding the use of β-blockers for hypertension, newer classes of β-blockers, their comparative advantages over other antihypertensive drugs, clinical evidence, and limitations of their use.",
author = "Shahid Akbar and Richards, {John R}",
year = "2018",
month = "1",
day = "1",
language = "English (US)",
isbn = "9781536133110",
pages = "45--78",
booktitle = "Beta-Blockers",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Beta-blockers for control of hypertension

T2 - Controversy, evidence, and current practice

AU - Akbar, Shahid

AU - Richards, John R

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Hypertension remains one of the most pressing clinical problems in medicine around the globe. Treatment of hypertension has been evolving over the past few decades but remains a challenge for clinicians to achieve the targeted goals of blood pressure in their patients. Different classes of pharmacological agents are available to choose from, each with specific advantages and disadvantages. Beta-blockers have been a dependable group of drugs for many years for treatment of acute and chronic hypertension; however, their routine use for hypertension has lately been a subject of discussion and controversy. Beta-blockers have now been relegated to third-line treatment for hypertension in many countries. This chapter reviews the controversies surrounding the use of β-blockers for hypertension, newer classes of β-blockers, their comparative advantages over other antihypertensive drugs, clinical evidence, and limitations of their use.

AB - Hypertension remains one of the most pressing clinical problems in medicine around the globe. Treatment of hypertension has been evolving over the past few decades but remains a challenge for clinicians to achieve the targeted goals of blood pressure in their patients. Different classes of pharmacological agents are available to choose from, each with specific advantages and disadvantages. Beta-blockers have been a dependable group of drugs for many years for treatment of acute and chronic hypertension; however, their routine use for hypertension has lately been a subject of discussion and controversy. Beta-blockers have now been relegated to third-line treatment for hypertension in many countries. This chapter reviews the controversies surrounding the use of β-blockers for hypertension, newer classes of β-blockers, their comparative advantages over other antihypertensive drugs, clinical evidence, and limitations of their use.

UR - http://www.scopus.com/inward/record.url?scp=85048382874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048382874&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85048382874

SN - 9781536133110

SP - 45

EP - 78

BT - Beta-Blockers

PB - Nova Science Publishers, Inc.

ER -